SR One Capital Management has led the RNA targeting drug developer’s latest round, participating alongside investors including Lilly Asia Ventures.

US-based genetic therapeutics developer Adarx Pharmaceuticals secured $75m yesterday in a series B round co-led by SR One Capital Management, the venture capital offshoot of pharmaceutical firm GlaxoSmithKline.

Lilly Asia Ventures, a corporate venturing arm of pharmaceutical firm Eli Lilly, also took part in the round, which was co-led by healthcare-focused investment firm OrbiMed and backed by real estate developer Sirona Capital.

Founded in 2019, Adarx is developing genetic drugs using RNA editing technology to target diseases including genetic,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn